Novo Nordisk’s Dual Narrative: Promising Hemophilia Data and Steady Buybacks vs. a Glitch in the Obe
Novo Nordisk ended the week at €43.32, notching a 1.29% gain in Friday’s session. The move capped a…
Novo Nordisk Juggles Promising Pill Rollout and Sobering Stock Metrics in Pivotal ADA Week
Wegovy oral pill sees 2M US prescriptions and UAE approval, but Novo Nordisk stock falls 42% as GLP-1…